Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00061126
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2003-05-21
Brief Title:
ABX-EGF a Monoclonal Antibody Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
Sponsor:
Abgenix
Organization:
Abgenix
Study Overview
Official Title:
A Clinical Trial Evaluating the Safety and Efficacy of ABX-EGF in Patients With Hormone Resistant Prostate Cancer With or Without Metastasis
Status:
COMPLETED
Status Verified Date:
2004-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body
Patients will be treated for a maximum of 48 doses 6 treatment courses 8 doses per course or until evidence of progressive disease
Patients will be treated for a maximum of 48 doses 6 treatment courses 8 doses per course or until evidence of progressive disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ABX-EGF | None | None | None |